Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1975 Dec;12(6):1290–1294. doi: 10.1128/iai.12.6.1290-1294.1975

Vi antigen from Salmonella typhosa and immunity against typhoid fever. 11. Safety and antigenicity in humans.

D M Levin, K H Wong, H Y Reynolds, A Sutton, R S Northrup
PMCID: PMC415434  PMID: 54336

Abstract

Safety and antigenicity of a purified preparation of Salmonella typhosa Vi antigen was evaluated in human volunteers. Dosages of Vi antigen at 25, 50, and 100 mug were less toxic than U.S. standard typhoid vaccine (lot 6A) containing 5 X 10(8) bacteria per dosage. Vi antigen in comparison with the standard typhoid vaccine induced higher hemagglutinating antibody but lower bactericidal antibody responses.

Full text

PDF
1290

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. CVJETANOVIC B., UEMURA K. THE PRESENT STATUS OF FIELD AND LABORATORY STUDIES OF TYPHOID AND PARATYPHOID VACCINES WITH SPECIAL REFERENCE TO STUDIES SPONSORED BY WORLD HEALTH ORGANIZATION. Bull World Health Organ. 1965;32:29–36. [PMC free article] [PubMed] [Google Scholar]
  2. Greisman S. E., Hornick R. B. Cellular inflammatory responses of man to bacterial endotoxin: a comparison with PPD and other bacterial antigens. J Immunol. 1972 Dec;109(6):1210–1222. [PubMed] [Google Scholar]
  3. Hornick R. B., Greisman S. E., Woodward T. E., DuPont H. L., Dawkins A. T., Snyder M. J. Typhoid fever: pathogenesis and immunologic control. N Engl J Med. 1970 Sep 24;283(13):686–691. doi: 10.1056/NEJM197009242831306. [DOI] [PubMed] [Google Scholar]
  4. LANDY M. Enhancement of the immunogenicity of typhoid vaccine by retention of the V1 antigen. Am J Hyg. 1953 Sep;58(2):148–164. doi: 10.1093/oxfordjournals.aje.a119596. [DOI] [PubMed] [Google Scholar]
  5. LANDY M., LAMB E. Estimation of Vi antibody employing erythrocytes treated with purified Vi antigen. Proc Soc Exp Biol Med. 1953 Apr;82(4):593–598. doi: 10.3181/00379727-82-20188. [DOI] [PubMed] [Google Scholar]
  6. LANDY M. Studies on Vi antigen. VI. Immunization of human beings with purified Vi antigen. Am J Hyg. 1954 Jul;60(1):52–62. doi: 10.1093/oxfordjournals.aje.a119703. [DOI] [PubMed] [Google Scholar]
  7. LANDY M., TRAPANI R. J., WEBSTER M. E., JAVIS F. G. Immunological properties of Vi antigen isolated by chemical fractionation and by electrophoresis. Tex Rep Biol Med. 1963;21:214–229. [PubMed] [Google Scholar]
  8. OSAWA E., MUSCHEL L. H. THE BACTERICIDAL ACTIONS OF O AND VI ANTIBODIES AGAINST SALMONELLA TYPHOSA. J Immunol. 1964 Feb;92:281–285. [PubMed] [Google Scholar]
  9. Pittman M., Bohner H. J. Laboratory assays of different types of field trial typhoid vaccines and relationship to efficacy in man. J Bacteriol. 1966 May;91(5):1713–1723. doi: 10.1128/jb.91.5.1713-1723.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. WEBSTER M. E., LANDY M., FREEMAN M. E. Studies on Vi antigen. II. Purification of Vi antigen from Escherichia coli 5395/38. J Immunol. 1952 Aug;69(2):135–142. [PubMed] [Google Scholar]
  11. Wong K. H., Feeley J. C., Northrup R. S., Forlines M. E. Vi antigen from Salmonella typhosa and immunity against typhoid fever. I. Isolation and immunologic properties in animals. Infect Immun. 1974 Feb;9(2):348–353. doi: 10.1128/iai.9.2.348-353.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Wong K. H., Feeley J. C., Pittman M. Effect of a Vi-degrading enzyme on potency of typhoid vaccines in mice. J Infect Dis. 1972 Apr;125(4):360–366. doi: 10.1093/infdis/125.4.360. [DOI] [PubMed] [Google Scholar]
  13. Wong K. H., Feeley J. C., Pittman M., Forlines M. E. Adhesion of Vi antigen and toxicity in typhoid vaccines inactivated by acetone or by heat and phenol. J Infect Dis. 1974 May;129(5):501–506. doi: 10.1093/infdis/129.5.501. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES